Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044005 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of Drug to Treat Schizophrenia
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00044005: Completed Phase 2 study, sponsored by Sumitomo Pharma America.
NCT00044005 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044005, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Primary Outcome
The primary objective of this 6-month open-label study was to evaluate the safety of 3 doses of lurasidone.
Interventions
- DRUG Lurasidone 40 mg
- DRUG Lurasidone 20 mg
- DRUG Lurasidone 80mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
What the finished NCT00044005 record still lists
NCT00044005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 3 interventions - of which Lurasidone 40 mg is the first listed.
NCT00044005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044005 about?
NCT00044005 is a clinical study titled "Safety and Tolerability Study of Drug to Treat Schizophrenia". The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
What is the current status of trial NCT00044005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2002-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00044005?
The interventions under investigation include: Lurasidone 40 mg (DRUG), Lurasidone 20 mg (DRUG), Lurasidone 80mg (DRUG).
Who is sponsoring clinical trial NCT00044005?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00044005's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia